Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities

Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities

Eun-mi Yu,1 Min Woo Hwang,2 Jeanny B Aragon-Ching1 1GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA; 2Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA, USACorrespondence: Jeanny B Aragon-Ching, Clinical Program Director of Genitourinary Cancers, Inova Schar Ca...

Full description

Bibliographic Details
Main Authors:	Yu EM, Hwang MW, Aragon-Ching JB
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-11-01
Series:	Research and Reports in Urology
Subjects:	prostate cancer metastasis castration-resistant prostate cancer epithelial mesenchymal transition androgen receptor pathway inhibitors poly-adp ribose pathway inhibitors
Online Access:	https://www.dovepress.com/mechanistic-insights-on-localized-to-metastatic-prostate-cancer-transi-peer-reviewed-fulltext-article-RRU

Similar Items

Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases
by: Yukiyoshi Hirayama, et al.
Published: (2022-11-01)

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape
by: Ashaar Al-Akhras, et al.
Published: (2024-01-01)

Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib
by: Riko Ikeda, et al.
Published: (2024-03-01)

RETRACTED: New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
by: Neha Thakur, et al.
Published: (2023-08-01)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
by: Xiangyu Chen, et al.
Published: (2023-10-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
by: Abhenil Mittal, et al.
Published: (2023-04-01)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
by: Sotaro Chikamatsu, et al.
Published: (2022-03-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
by: Jukapun Yoodee, et al.
Published: (2022-11-01)

Characterization of Proteins Regulated by Androgen and Protein Kinase a Signaling in VCaP Prostate Cancer Cells
by: Hye-Jin You, et al.
Published: (2021-10-01)

Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
by: Mariangela Calabrese, et al.
Published: (2023-12-01)

Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
by: Pier Vitale Nuzzo, et al.
Published: (2023-02-01)

Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer
by: Toros A. Dincman, et al.
Published: (2024-02-01)

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil
by: Aknar FC Calabrich, et al.
Published: (2023-04-01)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
by: Seta Derderian, et al.
Published: (2023-07-01)

How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
by: Turco F, et al.
Published: (2023-01-01)

Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer
by: AD Zarrabi, et al.
Published: (2011-06-01)

Research Progress on the Mechanism of Androgen Receptor Signaling Pathway in Castration-Resistant Prostate Cancer
by: Na Cui, et al.
Published: (2023-11-01)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
by: Takuya Tsujino, et al.
Published: (2023-10-01)

Metformin and Androgen Receptor-Axis-Targeted (ARAT) Agents Induce Two PARP-1-Dependent Cell Death Pathways in Androgen-Sensitive Human Prostate Cancer Cells
by: Yi Xie, et al.
Published: (2021-02-01)

Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use
by: Cheng-Kuang Yang, et al.
Published: (2023-04-01)

Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin
by: Yoshiyuki Miyazawa, et al.
Published: (2023-01-01)

Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target
by: Enrique A. Castellón, et al.
Published: (2022-11-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer
by: Francesco Lasorsa, et al.
Published: (2023-01-01)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
by: Hao-Wen Sim, et al.
Published: (2022-02-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Taizo Uchimoto, et al.
Published: (2021-01-01)

Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants
by: Demitria M. Vasilatis, et al.
Published: (2023-04-01)

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis
by: Omar Fahmy, et al.
Published: (2021-12-01)

Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
by: Carlo Cattrini, et al.
Published: (2021-09-01)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
by: Koji Hatano, et al.
Published: (2023-10-01)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)

Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under <i>Parg</i> Deficiency
by: Yuki Sonoda, et al.
Published: (2020-04-01)

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer
by: Xu Huang, et al.
Published: (2023-03-01)

PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment
by: Sarah Johnson, et al.
Published: (2022-05-01)

Molecular Mechanism of Oxidative Stress Mediated Androgen Receptor Signal Reactivation in Prostatic Cancer Progression
by: HENG Li, ZHANG Liguo, DONG Jingting, LI Zhiguo, CAO Fenghong
Published: (2022-02-01)

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
by: Stephanie Gleicher, et al.
Published: (2021-05-01)

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges
by: Yuki Kita, et al.
Published: (2018-09-01)

The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
by: Jennifer L. Bishop, et al.
Published: (2014-04-01)